Therapeutic Fungi – Microbials 2016


Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.


This project is one of the five winners of the call 2016 «Microbials – Direct Use of Micro-Organisms».

Project partners: CHUV, Service de pneumologie; University of Lausanne, Department of Fundamental Microbiology; Oslo University Hospital


Projekt-Nr.: GRS-055/16
Förderbeitrag: CHF 480'000
davon Löhne: CHF 345'000
Bewilligung: 02.11.2016
Dauer: 01.2017 - 01.2020
Handlungsfeld: Microbials, seit 2016

Microbial Treatment of Solid Tumors – Microbials 2016
Projekt nummerGRS-059/16 BudgetCHF 400'000 VerantwortlichSimon Ittig Laufzeit01.2017 - 12.2018

Effector delivery by Contractile Injection Machines – Microbials 2016
Projekt nummerGRS-058/16 BudgetCHF 352'000 VerantwortlichMartin Pilhofer Laufzeit01.2017 - 12.2019

A Specific Mechanosensitive Bacterial Tumor Therapy – Microbials 2016
Projekt nummerGRS-057/16 BudgetCHF 374'000 VerantwortlichAlexandre Persat Laufzeit05.2017 - 04.2020

Microorganism-based Biosensor – Microbials 2016
Projekt nummerGRS-056/16 BudgetCHF 450'000 VerantwortlichJan Wendelin Stark Laufzeit01.2017 - 12.2019

Therapeutic Fungi – Microbials 2016
Projekt nummerGRS-055/16 BudgetCHF 480'000 VerantwortlichBenjamin Marsland Laufzeit01.2017 - 01.2020


Dr. Benjamin Marsland, Centre hospitalier universitaire vaudois (CHUV), Service de pneumologie, Dept. of Medicine, Bureau CLE D02-206, Ch. des Boveresses, 1066 Epalinges (Schweiz), benjamin.notexisting@nodomain.commarsland@chuv.notexisting@nodomain.comch


In western societies there has been a striking increase in the incidence of inflammatory diseases such as asthma, autoimmunity and inflammatory bowel disease over recent decades. The general consensus in the field is that major underlying causes of this increase are changes in lifestyle, diet and hygiene. A commonality between all of these factors is shifts in the constituents of the microbiota. Accordingly, there has been a surge of interest in trying to manipulate the microbiota with bacterial pre- or pro-biotics, for example, as a means of improving human health. Based upon preliminary data, we propose that bacteria are only one aspect of this phenomenon, and that fungi represent an untapped resource for shaping the microbiome and consequently disease susceptibility and development. In this project proposal we aim to identify which fungi in mice and humans are responsible for influencing inflammatory diseases, such as asthma. We aim to decipher the mechanisms through which fungi impact upon disease and to perform preclinical efficacy studies to establish which fungi hold the greatest promise for further development as novel future therapeutics. To achieve these goals, we plan to take an interdisciplinary approach incorporating preclinical immunology, computational modeling and a clinical cohort. Our hypotheses are based upon preliminary data and we have established the required models and collaborations in order to achieve our goals. Therapeutic targeting of the fungal ‘mycobiome’ could be the step-change needed to reduce inflammatory diseases, improve human health and lower the burden that these diseases place upon society and healthcare systems.

Was ist das Besondere an diesem Projekt?

This is a highly innovative and unique project addressing a new concept in microbiome research–harnessing fungi for their therapeutic potential. The approach is interdisciplinary, with a cross-over between immunology, clinical studies and computational modeling approaches.


A model has been generated whereby mice are depleted of fungi and we see they become more susceptible to asthma. We now aim to understand the mechanism by which fungi can protect against asthma.


None so far


None so far


CHUV – Microbiota and Respiratory Disease Research
Oslo Universitetssykehus

Am Projekt beteiligte Personen

Assoc. Prof. Dr. Benjamin Marsland, Chef de secteur de recherche, phone +41 (0)21 314 1378

Letzte Aktualisierung dieser Projektdarstellung